Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure
- PMID: 12974145
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure
Abstract
The purpose of the study was to find out differences between treatments of diabetes type 2 after secondary oral antidiabetic drug failure. Three different methods of treatment were compared: lispro insulin in combination with metformin, glimepiride and metformin combination or two daily doses of biphasic insulin 30/70 together with bed-time NPH insulin. The study included 87 patients with diabetes mellitus type 2 randomly distributed into 3 different treatment groups. Fasting and postprandial glucose were analyzed by enzymatic colorimetric method and HbA1c was measured by ion exchange chromatography. HbA1c significantly decreased in all three study groups. The decrease was mostly expressed among patients treated with lispro and metformin. When focused on postprandial glucose control, antihyperglycemic metformin and insulin lispro therapy has greater impact on the overall metabolic control (decrease in level of HbA1c) in comparison with the above mentioned more traditional approaches.
Similar articles
-
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.Metabolism. 2009 Aug;58(8):1059-66. doi: 10.1016/j.metabol.2009.03.007. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19394976 Clinical Trial.
-
A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.Clin Invest Med. 2001 Dec;24(6):292-8. Clin Invest Med. 2001. PMID: 11767232 Clinical Trial.
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.Diabetes Obes Metab. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. Epub 2007 Jun 26. Diabetes Obes Metab. 2007. PMID: 17593236 Clinical Trial.
-
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.Diabetes Obes Metab. 2008 Dec;10(12):1167-77. doi: 10.1111/j.1463-1326.2008.00907.x. Epub 2008 May 20. Diabetes Obes Metab. 2008. PMID: 18494804 Review.
-
[Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].Przegl Lek. 2009;66(7):388-93. Przegl Lek. 2009. PMID: 20043582 Review. Polish.
Cited by
-
Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2. Cochrane Database Syst Rev. 2016. PMID: 27640062 Free PMC article. Review.
-
Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.Int J Endocrinol Metab. 2018 Apr 21;16(2):e65600. doi: 10.5812/ijem.65600. eCollection 2018 Apr. Int J Endocrinol Metab. 2018. PMID: 30008760 Free PMC article. Review.
-
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.CMAJ. 2009 Feb 17;180(4):385-97. doi: 10.1503/cmaj.081041. CMAJ. 2009. PMID: 19221352 Free PMC article.
-
Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens.J Diabetes Res. 2016;2016:5374931. doi: 10.1155/2016/5374931. Epub 2016 Sep 28. J Diabetes Res. 2016. PMID: 27761472 Free PMC article.
-
Insulin lispro: a review of its use in the management of diabetes mellitus.Drugs. 2007;67(3):407-34. doi: 10.2165/00003495-200767030-00006. Drugs. 2007. PMID: 17335298 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical